

Salmonellosis Associated with Chicks and Ducklings — Michigan and Missouri, Spring 1999

During the spring of 1999, outbreaks of salmonellosis associated with handling chicks and ducklings occurred in Michigan and Missouri. This report summarizes the epidemiologic information for the outbreaks and provides an overview of legislative efforts to control the distribution of chicks and ducklings. These outbreaks demonstrate that handling chicks and ducklings is a health risk, especially for children, and highlight the need for thorough handwashing after contact with chicks, ducklings, and other young fowl.

Michigan

In May 1999, the Michigan Department of Community Health (MDCH) was notified of an increase in *Salmonella* serotype Infantis infections with closely related pulsed-field gel electrophoresis (PFGE) patterns; 21 case-patients were reported with onset of illness during April 1–July 31, 1999. Ages of infected persons ranged from 8 days to 82 years (mean: 25 years); eight (38%) were aged <10 years. Twelve (57%) were female. Symptoms reported during patient interviews included diarrhea (81%), fever (57%), bloody diarrhea (24%), and vomiting (14%). Three patients were hospitalized. Overall, 17 (82%) patients reported direct and/or indirect contact with young fowl: eight (38%) with chicks, two (10%) with ducklings, one (5%) with pheasant, and six (29%) with multiple species, including chicks and ducklings. Of the young fowl that were traceable, 88% were shipped from a single hatchery.

MDCH conducted a case-control study to identify exposures associated with illness. Nineteen patients were enrolled and were matched by age and place of residence to 37 healthy controls using sequential-digit dialing. During the 5 days before illness onset, 14 (74%) of 19 patients had direct contact with young fowl or resided in a household that raised fowl (chicks, ducklings, goslings, pheasants, and/or turkeys) compared with six (16%) of 37 controls (matched odds ratio [MOR]=20; 95% confidence interval [Cl]=3–378). In several households, young birds were kept inside the home. One child kept young birds in his bedroom and another carried chicks inside his jacket.

MDCH, with assistance from the Michigan Department of Agriculture (MDA), visited the implicated hatchery in September 1999. During the spring, the hatchery shipped approximately 100,000 birds per week by mail order directly to customers and to several feed and farm supply retail outlets across the state. Fowl were shipped in lots of 25 to 100 birds, and usually were raised for backyard use (i.e., meat and egg production for

U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES

Salmonellosis Associated with Chicks and Ducklings - Continued

the family). *S.* Infantis with the outbreak PFGE pattern was recovered from three of 47 environmental samples and five of 33 bird samples taken at the hatchery. Other *Salmonella* serotypes also were isolated from the environmental samples, including serotypes Montevideo (seven), Chester (one), and Mbandaka (one).

Missouri

In April 1999, the Missouri Department of Health (MDOH) noted a cluster of *Salmo-nella* serotype Typhimurium infections with an identical PFGE pattern; 40 case-patients were identified with onset of illness during April 4–May 30, 1999. The ages of infected persons ranged from 8 months to 46 years (mean: 13 years); 28 (70%) were age <20 years; 23 (58%) were male. Symptoms reported by the 33 patients interviewed included fever (42%), bloody diarrhea (27%), stomach cramps (27%), and vomiting (21%). Three patients were hospitalized. Overall, 32 (97%) persons reported exposure to young fowl: 18 (56%) were exposed to chicks, 10 (31%) to ducklings, three (9%) to both chicks and ducklings, and one (3%) to a young turkey.

MDOH conducted a case-control study of persons exposed to chicks or ducklings to identify whether specific behaviors were associated with illness. Twenty case-patients were enrolled; 40 controls who had been exposed to chicks and ducklings during the same time were identified through media advertisements and word-of-mouth. During the 4 weeks before onset of patient illness, chicks or ducklings that were identified as ill by the patient or handler were associated with human illness (odd ratio [OR]=21; 95% Cl=2–508); handwashing after handling fowl was protective against illness (OR=0.0; 95% Cl=0.0–0.2).

Legislative Efforts

During February 2000, CDC contacted 51 state and territorial public health departments to ascertain laws on the sale of baby fowl to noncommercial distributors and private persons; 28 (55%) responded. Ten (36%) states have laws restricting the sale of baby fowl for noncommercial purposes, including the sale of fowl aged <3 weeks (Indiana and Maryland), <4 weeks (Ohio and Pennsylvania), <8 weeks (Massachusetts and Virginia), and <12 weeks (Connecticut). In addition, Connecticut, Ohio, and Virginia require fowl to be sold in groups of greater than five birds. Illinois prohibits the sale of chicks during the Easter season, and Kansas requires persons to have a temporary or permanent license to sell chicks.

Reported by: S Bidol, MPH, MG Stobierski, DVM, B Robinson-Dunn, PhD, J Massey, DrPH, W Hall, MD, M Boulton, MD, State Epidemiologist, Michigan Dept of Community Health. M Warwick, MD, M Borst, S Wiedlocher, Missouri Dept of Health. State Br, Div of Applied Public Health Training, Epidemiology Program Office; Foodborne and Diarrheal Diseases Br, Div of Bacterial and Mycotic Diseases, National Center for Infectious Diseases; and an EIS Officer, CDC.

Editorial Note: Although most of the 1.4 million human salmonellosis cases that occur annually in the United States are caused by foodborne sources (1), direct contact with animals, particularly reptiles and occasionally birds, also may be a source of infection (2-4). Most reptiles and many birds shed *Salmonella* in their feces. Humans become infected when contaminated food, hands, or other objects are placed in the mouth; therefore, handwashing is critical to prevent *Salmonella* infections following direct or indirect contact with animals. The Missouri outbreak described in this report and previous outbreaks (3,4) demonstrate that handling young fowl can be a risk for *Salmonella* infections, particularly in children who receive fowl as gifts during Easter; children have

Salmonellosis Associated with Chicks and Ducklings - Continued

more frequent hand-to-mouth contact and are less likely to practice handwashing after handling fowl. The Michigan outbreak describes the risk for infection associated with the backyard production of fowl.

Prevention efforts, such as sales restrictions and consumer education, may be difficult because selling pet fowl and raising backyard fowl are largely unregulated. Several states responding to the survey reported laws that restrict the sale of chicks, ducklings, and other young fowl. Some of these restrictions are based on previous reports of chickassociated and duckling-associated salmonellosis during Easter (5). Enforcement also may be difficult because young fowl can be purchased by mail and Internet orders from out-of-state hatcheries. State-mandated point-of-sale educational material may be effective in educating consumers about the risk for salmonellosis. States may wish to join Michigan and Missouri in issuing a press release during the spring of 2000 to raise public awareness about the risk for *Salmonella* infections posed by young fowl. MDCH, MDA, and MDOH have developed safety instructions to be distributed with young fowl that emphasize the importance of handwashing and supervision of young children interacting with young fowl.

To prevent the transmission of *Salmonella* from chicks, ducklings, and other young fowl to humans, persons should avoid contact with feces and carefully wash their hands with soap and water after handling young fowl or anything that has come in contact with them. Chicks, ducklings, and other young fowl may not be appropriate pets for children and should not be kept in households with infants, children aged <5 years, or immunocompromised persons. During investigations of *Salmonella* infections, especially during spring and Easter, health-care workers and public health personnel should consider contact with young fowl as a potential source and obtain cultures from these animals if they are suspected as the source of infection.

References

- 1. Mead PS, Slutsker L, Dietz V, et al. Food-related illness and death in the United States. J Emerg Infect Dis 1999;5:607–25.
- 2. Mermin J, Hoar B, Angulo FJ. Iguanas and *Salmonella Marina* infection in children: a reflection of the increasing incidence of reptile-associated salmonellosis in the United States. Pediatrics 1997;99:399–402.
- 3. CDC. *Salmonella hadar* associated with pet ducklings—Connecticut, Maryland, and Pennsylvania, 1991. MMWR 1992;41;185–7.
- 4. CDC. *Salmonella* serotype Montevideo infections associated with chicks—Idaho, Washington, and Oregon, spring 1995 and 1996. MMWR 1997;46:237–9.
- Crawford KL. Legislation concerning the sale of live baby fowl as pets. In: Salmonella surveillance report 1967. Atlanta, Georgia: US Department of Health, Education and Welfare, Public Health Service, CDC, 1967 (publication no. 61).

Measles Outbreak — Netherlands, April 1999–January 2000

On June 21, 1999, a cluster of five cases of measles was reported among the 390 students attending a religion-affiliated elementary school in the Netherlands. Persons belonging to this religious denomination routinely do not accept vaccination. Municipal health services (MHSs) investigated and found 160 suspected measles cases among children attending the school. By February 4, 2000, 2961 measles cases, including three measles-related deaths, had been reported by 35 MHSs to the national registry. This report summarizes the investigation of the measles outbreak in the Netherlands,

Measles — Continued


which indicated that measles can be a severe disease among unvaccinated populations in the Netherlands.

Measles is a notifiable disease in the Netherlands, and cases that occurred during this outbreak were reported by physicians to the local MHS as part of routine surveillance. The vaccination status of ill persons was reviewed based on written records kept by reporting physicians and sent to the vaccination registry. In April 1999, the first cluster of measles cases occurred, followed by the reported elementary school outbreak in June. No cases of measles with onset in May were reported, and transmission was low during June and July (Figure 1). When schools reopened in August, the number of cases increased. The outbreak peaked during October–November, then decreased rapidly. As of February 4, the last reported cases had onset during the week of January 16. Since then, the number of reported cases has decreased substantially, suggesting that the outbreak is ending.

From April 15, 1999, to February 4, 2000, 2961 cases of measles were reported in 35 (67%) of the country's 52 MHSs; 2317 (78%) were reported by 10 MHSs. All reporting municipalities have large communities affiliated with the religious group. Of the 105 case-patients tested for measles immunoglobulin type M, 100 (95%) had serologically confirmed measles.

Complications among acute measles case-patients were assessed by telephone follow-up with reporting physicians; 510 (17%) cases had one or more complications and/or hospitalizations (Table 1). Three patients died as the result of measles complications: one child aged 2 years had an underlying cardiac disorder and subsequent cardiac failure, one child aged 3 years developed myocarditis, and one adolescent aged 17 years

FIGURE 1. Reported number of measles cases, by week of disease onset and vaccination status — Netherlands, April 15, 1999–February 4, 2000



Vol. 49 / No. 14

Measles — Continued

 TABLE 1. Complications from reported cases of measles — Netherlands,

 April 15, 1999–February 4, 2000

Complication	No.	(%)	
Death	3	(0.1)	
Hospitalization for encephalitis	5	(0.2)	
Hospitalization for other reasons	63	(2.1)	
Pneumonia	130	(4.4)	
Otitis media	170	(5.7)	
Pneumonia and otitis media	26	(0.9)	
Other respiratory disorders	56	(1.9)	
Other	57	(1.9)	
No complications	2451	(82.8)	
Total	2961	(100.0)	

developed kidney failure and acute respiratory distress syndrome. Sixty-eight (2.2%) persons were reported hospitalized: 37 (1.2%) for pneumonia, seven (0.2%) for dehydration, five (0.2%) for encephalitis, four (0.1%) for high fever, three (0.1%) for shortness of breath, two (0.1%) for severe otitis media, two (0.1%) for croup, and six (0.2%) for other reasons. Two persons developed measles while hospitalized for other reasons.

Of the 2882 patients whose ages were known, the median age was 6 years (range: 0–52 years): 95 (3%) were aged <1 year; 949 (33%), aged 1–4 years; 1282 (44%), aged 5–9 years; 382 (13%), aged 10–14 years; 87 (3%), aged 15–19 years; and 87 (3%), aged \geq 20 years. Information on vaccination status was available for 2907 persons; 2770 (95%) were unvaccinated and 137 (5%) were vaccinated children. Of the 137, 117 (85%) were aged <9 years and all had received one dose of measles, mumps, and rubella vaccine (MMR); in 20 (15%) children the number of doses was unknown. Based on data from the national registry, 2749 persons whose ages were known were unvaccinated: 2317 (84%) persons eligible for vaccination were not vaccinated for religious reasons and 173 (6%) for other reasons (e.g., lack of concern about measles or concern about adverse events); 187 (7%) were not eligible for vaccination: 160 (85%) were aged <14 months (the recommended age for administration of the first dose of measles vaccine), 20 (11%) were born before 1976 (the year measles vaccination was introduced), and seven (4%) had a contraindication for measles vaccination. For the remaining 72 (3%) unvaccinated persons, the reason for not being vaccinated was unknown.

In response to the outbreak in the Netherlands, on July 1, control activities were implemented, including 1) tracing contacts of cases, 2) offering vaccine or immunoglobulin to susceptible contacts, 3) alerting all secondary-care and tertiary-care hospitals about the measles outbreak, 4) requesting general physicians to report all suspected cases, 5) conducting catch-up vaccination sessions at MHSs and mother and child clinics, 6) increasing media attention about undervaccination, and 7) urging parents to complete vaccination of children.

Reported by: JE van Steenbergen, National Coordination Center for Communicable Disease Outbreak Management; S van den Hof, National Institute for Public Health and the Environment; MW Langendam, Municipal Health Svc, Amsterdam; JHTC van de Kerkhof, Municipal Health Svc, Zuid-Holland Zuid; WLM Ruijs, Municipal Health Svc, Rivierenland, Netherlands. Communicable Diseases and Immunization Unit, European Regional Office, World Health Organization (WHO), Copenhagen, Denmark; Vaccines and Biologicals Dept, WHO, Geneva, Switzerland. Respiratory and Enteric Viruses Br, Div of Viral and Rickettsial Diseases, National

Measles — Continued

Center for Infectious Diseases; Vaccine Preventable Disease Eradication Div, National Immunization Program, CDC.

Editorial Note: The three measles-related deaths and 68 hospitalizations that occurred among 2961 cases in the Netherlands indicate that measles can be severe and may result in death even in industrialized countries. Rates of complications reported in this outbreak are comparable with those in the United States and other industrialized countries (1).

Measles notification and vaccination began in 1976 in the Netherlands, where measles epidemics have occurred every 5–7 years: 1976, 1983, 1988, 1992–1993, and 1999–2000. Since 1987, two doses of MMR have been recommended at age 14 months and 9 years. Measles vaccination is not mandatory for entry into school in the Netherlands. During 1997–1999, nationwide coverage of children for both doses was reported between 95% and 96% (*2*). However, coverage was not distributed uniformly throughout the country. In 1999, coverage ranged from 53% to 90% in municipalities that had a high percentage of residents who were members of a particular group that refrains from vaccination on religious grounds (*2*). This community in the Netherlands, estimated at 300,000 persons (2% of the overall population) lives as a close social network in a circumscribed geographic area mostly in the provinces of Gelderland, Utrecht, Zuid-Holland, and Zeeland. Approximately half of the 4%–5% of unvaccinated persons in the Netherlands are members of this group. Although the Netherlands has high overall MMR coverage, 36 (7%) of 539 municipalities have one-dose coverage of <90%.

Although measles is more severe in malnourished or immunosuppressed persons, severe disease or death may result in persons with no underlying illness. Measles vaccine is a highly effective method for preventing this disease, and lack of vaccination resulted in this outbreak. Similar to the outbreak of poliomyelitis among religious communities in 1992 (*3,4*), measles spread from the Netherlands to Canada through visiting relatives. The resulting outbreak in Canada was limited to 17 cases within the religious community possibly because stringent control measures were taken (*5*).

Until measles is eradicated worldwide, epidemics will continue to occur periodically in the Netherlands. The World Health Organization (WHO) has established goals to eliminate measles as an indigenous disease from the Region of the Americas by the end of 2000, the European Region by 2007, and the Eastern Mediterranean Region by 2010. To reach these goals, the WHO regional office for Europe has conducted workshops aimed at assisting participating countries to develop an elimination strategy based on the percentage of persons susceptible to measles in their population. In addition to these activities, increased commitment at the regional and national levels is needed to eliminate measles in the European Region (6).

References

- 1. CDC. Measles, mumps, and rubella—vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1998:47(no. RR-8).
- 2. Anonymous. Vaccinatietoestand Nederland per 1 januari 1999 [Dutch]. The Hague, the Netherlands: Inspectorate of Health, 2000.
- 3. CDC. Update: poliomyelitis outbreak—Netherlands, 1992. MMWR 1992;41:917–9.
- CDC. Isolation of wild poliovirus type 3 among members of a religious community objecting to vaccination—Alberta, Canada, 1993. MMWR 1993;42:337–9.
- 5. van de Berichten LCI. Mazelenbestrijding in Canada [Dutch]. In: Ruijs H, ed. Infectieziekten Bulletin 2000;11:14.

Vol. 49 / No. 14

MMWR

Measles — Continued

 Ramsey M, Expanded Programme on Immunization in the European Region of the World Health Organization. Measles: a strategic framework for the elimination of measles in the European Region, February 1997. Copenhagen, Denmark: World Health Organization, 1999.

Fatal Yellow Fever in a Traveler Returning from Venezuela, 1999

On September 28, 1999, a previously healthy 48-year-old man from California sought care at a local emergency department (ED) and was hospitalized with a 2-day history of fever (102 F [38.9 C]), chills, headache, photophobia, diffuse myalgias, joint pains, nausea, vomiting, constipation, upper abdominal discomfort, and general weakness. On September 26, he had returned from a 10-day trip to Venezuela. On September 29, an infectious disease physician from the ED contacted the Marin County Health Department (MCHD) about the patient's symptoms; MCHD reported his illness to the California Department of Health Services (CDHS) as a suspected case of viral hemorrhagic fever. This report describes the investigation of the case.

On admission to the hospital, physical examination revealed icteric sclerae and tenderness in the upper abdomen. Multiple red papular lesions with excoriations consistent with recent mosquito bites were seen on his lower legs and feet. No hepatosplenomegaly or lymphadenopathy was noted. Laboratory results indicated markedly elevated serum bilirubin (5.9 mg/dL) and liver enzymes (alanine aminotransferase: >5000 U/L; aspartate aminotransferase: >3750 U/L; and alkaline phosphatase: 194 U/L), leukopenia (white cell count: 3.4x10³/mm³ with 82% segmented, 2% bands, and 2% atypical lymphocytes), thrombocytopenia (platelet count: 77,000/mm³), and evidence of acute renal failure (creatinine: 5.9 mg/dL; potassium: 6.4 mmol/L; and bicarbonate: 16 mmol/L).

A preliminary diagnosis of hemorrhagic fever syndrome was made, and the patient was placed on doxycycline and ceftriaxone. Cultures of blood and urine were negative for bacterial pathogens. Blood smears for malaria were negative. On October 1, the patient developed general seizures and upper respiratory obstruction. He was placed on mechanical ventilation and transferred to the intensive care unit. His condition deteriorated rapidly, with severe coagulopathy and cardiac arrhythmias. He died on October 4.

On October 7, an autopsy of the chest and abdomen was performed at the University of California San Francisco Medical Center. Histopathologic examination of the liver showed extensive necrosis, steatosis, and numerous Councilman bodies compatible with fulminant yellow fever (YF) hepatitis. Evidence of disseminated angioinvasive aspergillosis involving the lungs, heart, kidneys, adrenal glands, small and large bowel, stomach, and disseminated intravascular coagulation also was seen. Specimens of the liver were examined at CDC; YF viral antigens were found by immunohistochemistry (IHC) and YF virus-specific nucleic acids by polymerase chain reaction. Other IHC tests were negative for dengue virus, leptospira, New World arenaviruses, spotted fever group rickettsiae, and hantavirus. The patient's serum was tested by CDHS; no antibody to YF virus (17D) was detected by immunofluorescence in serum drawn September 28, but an IgG titer of 1:128 and an IgM titer of >1:80 were detected in serum drawn October 1.

During September 16–25, the patient had traveled with six companions to rainforests in southern Venezuela (Amazonas State). He experienced multiple mosquito bites during his visit despite using DEET-based repellents. Before his trip, the patient had received tetanus toxoid, typhoid vaccine, hepatitis A vaccine, and malaria prophylaxis, but not YF

Yellow Fever — Continued

vaccine. The six travel companions were contacted by CDHS about their health and vaccination status; none had become ill during or following the trip. Five had received YF vaccine before travel. The unvaccinated traveler's serum was negative for YF virus antibody tested at CDC by enzyme-linked immunosorbent assay.

Reported by: F Schwartz, MD, Marin County Health Dept, San Rafael; F Drach, MD, ME Guroy, MD, San Rafael; J Olson, MD, J Rabban, MD, H Sanchez, MD, Univ of California San Francisco, San Francisco; MS Ascher, MD, CA Glaser, MD, SB Werner, MD, DJ Vugia, MD, Acting State Epidemiologist, California Dept of Health Svcs. Infectious Disease Pathology Activity, Div of Viral and Rickettsial Diseases; Arbovirus Diseases Br, Div of Vector-Borne Infectious Diseases; Surveillance and Epidemiology Br, Div of Quarantine, National Center for Infectious Diseases; and an EIS Officer, CDC.

Editorial Note: This report describes the second case of imported fatal YF in a U.S. resident returning from South America since 1996, and the first such cases since 1924. Neither patient had received YF vaccine before travel. In the case described in this report, viral hemorrhagic fever was suspected and reported to the local health department. Histopathology, IHC studies, nucleic acid testing, and serology all demonstrated that the traveler died of YF complicated by angioinvasive aspergillosis. In 1996, a Tennessee resident returned from a 9-day trip to Brazil with fever, headache, and myalgias (*1*). He died 10 days after onset of symptoms, and YF virus was identified from tissue culture.

YF occurs in at least seven tropical South American countries (Bolivia, Brazil, Colombia, Ecuador, French Guiana, Peru, and Venezuela) and much of sub-Saharan Africa (2). The sylvatic cycle involves nonhuman primates and mosquitoes that breed in tree holes (3). Persons living or working in proximity to such jungle or forest habitats who are bitten by infected mosquitoes can develop "jungle YF." Another cycle exists between humans and *Aedes aegypti* mosquitoes. *Ae. aegypti* mosquitoes are present in most urban centers of South and Central America, the Caribbean, and parts of the southern United States; persons in these areas are at risk for urban YF infection. YF has not been reported from India or other parts of Asia despite the presence of *Ae. aegypti* (4).

World Health Organization (WHO) data suggest that YF transmission is increasing (4,5). After adjustments for underreporting, WHO estimates that approximately 200,000 YF cases occur each year, most in sub-Saharan Africa (4). Concomitant with increased YF transmission, the number of travelers from the United States to South America and Africa has more than doubled since 1988 (6). These travelers may be at risk for YF unless precautions are taken, including receipt of YF vaccine.

YF is one of three diseases (the others are plague and cholera) subject to international quarantine regulations (7). CDC is required to notify WHO of all YF cases in the United States within 24 hours. Accordingly, all suspected and confirmed cases should be reported immediately through local and state health departments to CDC's National Center for Infectious Diseases, Division of Quarantine (DQ), telephone (404) 639-8100; acute and convalescent-phase serum should be collected and sent for viral isolation and diagnosis to CDC's National Center for Infectious Diseases, Division of Vector-borne Infectious Diseases, telephone (970) 221-6400. CDC's DQ also is responsible for certifying YF vaccination centers in the United States. Since September 1, 1977, CDC has delegated to state and territorial health departments the responsibility to designate and supervise nonfederal YF vaccination centers within their jurisdictions. The location of certified U.S. YF vaccination centers is available from local and state health departments. If YF vaccine is medically contraindicated, health-care providers should supply

Vol. 49 / No. 14

MMWR

Yellow Fever — Continued

persons with a letter listing reasons for not vaccinating, and persons should carry this with them when traveling. Details of vaccine recommendations and requirements of individual countries are available from the CDC World-Wide Web site, http://www.cdc.gov/travel (2).

CDC recommends YF vaccination for travelers to countries reporting YF (2). Vaccination also is recommended for travel outside urban areas of countries that officially do not report the disease but are in the YF-enzootic zone. Travelers should also take protective measures to reduce contact with mosquitoes; these include wearing clothes that cover most of the body, staying in well-screened areas, using insect repellent (containing DEET at a concentration of <35% are recommended) on exposed skin and clothing, and sleeping under bed nets treated with permethrin or deltamethrin insecticides.

References

- 1. McFarland JM, Baddour LM, Nelson JE, et al. Imported yellow fever in a United States citizen. Clin Infect Dis 1997;25:1143–7.
- 2. CDC. Health information for international travel 1999–2000. Atlanta, Georgia: US Department of Health and Human Services, 1999. Available at http://www.cdc.gov/travel.
- 3. Monath TP. Yellow fever. In: Plotkin SA, Orenstein WA, eds. Vaccines. 3rd ed. Philadelphia, Pennsylvania: WB Saunders, 1999:815–79.
- Robertson SE, Hull BP, Tomori O, Bele O, LeDuc JW, Esteves K. Yellow fever: a decade of reemergence. JAMA 1996;276:1157–62.
- 5. World Health Organization. Yellow fever, 1996-1997. Wkly Epidemiol Rec 1998;73:354-9.
- International Trade Administration. U.S. resident travel to Canada, Mexico and overseas countries historical visitation outbound—1988–1998. Available at: http:// www.tinet.ita.doc.gov/research/reports/basic/national. Accessed April 12, 2000.
- 7. World Health Organization. International health regulations (1969): third annotated edition. Geneva, Switzerland: World Health Organization, 1983:10–2.

Notice to Readers

CDC Launches Internet Site in Spanish

CDC has launched its Spanish language web site, CDC En Español, on the World-Wide Web at http://www.cdc.gov/spanish/. It is also accessible from the left navigation side bar of the CDC home page.

CDC En Español is not a translation of the English language web site but is a site tailored to Hispanic/Latino populations. It provides health-related information to the Hispanic/Latino professional and to the Spanish-speaking community. The site also includes information directed at special groups, such as adolescents, students, teachers, patients, health-care providers, women, and men.


Included is information from the CDC and Agency for Toxic Substances and Disease Registry (ATSDR) centers, institutes, and offices and appropriate links to other key federal agency web sites that are important to the Hispanic/Latino community. CDC En Español provides an opportunity for CDC/ATSDR and its national and international partners to access common information and discuss issues. Questions related to CDC En Español can be sent by e-mail to spanish@cdc.gov.

Notice to Readers

Satellite Broadcast on Geographic Information System

A satellite broadcast on Geographic Information System (GIS), "GIS in Public Health: Using Mapping and Spatial Analysis Technologies for Health Protection," is scheduled for May 11, 2000, from noon to 2:30 p.m. eastern daylight time. This broadcast, produced jointly by CDC and the Agency for Toxic Substances and Disease Registry, will provide an overview of GIS applications in public health, environmental health, and health-care practice, including research and surveillance using GIS. GIS provides a mechanism for layering health, demographic, environmental, and other data in a geographic format to facilitate analysis and highlight patterns of health-related occurrences. The program is intended to assist participants in identifying ways in which GIS can be useful to their own health professions. It will include demonstrations of GIS technology and show how GIS has helped health professionals understand health issues. Additional information is available on the World-Wide Web at http://www.cdc.gov/phtn/gis/gis.htm, or telephone (404) 639-6338.

307





Beyond Historical Limits

*No measles cases were reported for the current 4-week period, yielding a ratio for week 14 of zero (0).

[†] Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

TABLE I. Summary — provisional cases of selected notifiable diseases, United States, cumulative, week ending April 8, 2000 (14th Week)

		Cum. 2000		Cum. 2000
Anthrax		-	HIV infection, pediatric*	32
Brucellosis*		7	Plaque	2
Cholera		-	Poliomyelitis, paralytic	-
Congenital ru	bella syndrome	1	Psittacosis*	4
Cyclosporiasi		4	Rabies, human	-
Diphtheria		-	Rocky Mountain spotted fever (RMSF)	29
Encephalitis:	California* serogroup viral	2	Streptococcal disease, invasive Group A	852
•	eastern equine*	-	Streptococcal toxic-shock syndrome*	32
	St. Louis*	-	Syphilis, congenital [¶]	10
	western equine*	-	Tetanus	4
Ehrlichiosis	human granulocytic (HGE)*	13	Toxic-shock syndrome	36
	human monocytic (HME)*	1	Trichinosis	2
Hansen Disea	se*	11	Typhoid fever	77
Hantavirus pu	Ilmonary syndrome*†.	-	Yellow fever	
Hemolytic ure	emic syndrome, post-diarrheal*	23		

-: no reported cases *Not notifiable in all states. *Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases (NCID). *Updated monthly from reports to the Division of HIV/AIDS Prevention–Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention (NCHSTP), last update March 26, 2000. *Updated from reports to the Division of STD Prevention, NCHSTP.

								Escherichia	<i>coli</i> O157:H7		
	AIE	-	Chlan			oridiosis	NET		PH		
Reporting Area	Cum. 2000 [†]	Cum. 1999	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999	
UNITED STATES	10,143	11,376	134,665	175,255	302	395	352	298	201	251	
NEW ENGLAND Maine N.H. 8 Vt. Mass. R.I. 21 Conn.	666 11 19 1 446 30 179	529 5 284 4 354 624 117	5,739 286 288 152 2,688 596 1,705	5,690 191 - 132 2,499 2 1,984	15 3 2 8 2 -	19 1 4 1 12 - 3	32 3 1 10 1 14	43 4 3 20 12	28 2 3 7 1 13	38 - 19 15	
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	2,471 131 1,441 563 336	2,834 359 1,443 593 439	7,096 N 464 1,107 5,525	21,080 N 10,053 3,371 7,656	25 18 4 - 3	76 26 39 4 7	35 35 - N	15 10 2 3 N	39 32 - 2 5	7 1 - 6 -	
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	921 139 88 542 114 38	842 148 124 402 125 43	23,677 6,179 3,192 6,759 5,831 1,716	28,073 8,685 3,234 7,286 5,868 3,000	49 14 3 - 9 23	65 9 5 7 10 34	52 15 10 16 11 N	55 23 10 11 11 N	10 5 1 2 2	41 12 8 7 6	
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. Nebr. Kans.	203 44 15 90 - 2 13 39	246 39 30 99 3 5 17 53	6,916 1,658 991 1,287 61 469 763 1,687	9,990 2,073 857 3,655 243 521 998 1,643	23 4 3 1 3 2 2	26 11 3 - 2 3 2	76 18 15 34 2 1 2 4	71 12 8 6 2 1 28 14	48 22 4 12 2 1 4 3	61 16 2 5 2 1 35	
S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	2,848 45 271 186 221 15 128 232 300 1,450	3,163 40 344 118 177 19 197 313 349 1,606	26,955 812 2,734 854 3,854 450 5,495 669 5,015 7,072	35,461 797 3,620 N 3,774 5,88 5,686 5,642 7,311 8,043	53 1 5 - 2 - 4 - 32 9	64 5 3 1 - 1 - 42 12	33 5 6 2 8 2 3 7	27 1 - 6 - 7 1 1 1	16 - 1 5 1 2 - 3 4	18 - - 4 1 6 1 U 6	
E.S. CENTRAL Ky. Tenn. Ala. Miss.	415 56 172 120 67	490 70 211 109 100	12,324 2,166 3,303 4,602 2,253	12,715 2,088 3,882 3,543 3,202	11 - 1 7 3	4 1 2 1	21 7 7 1 6	23 6 9 4 4	13 3 8 - 2	12 5 3 3 1	
W.S. CENTRAL Ark. La. Okla. Tex.	824 42 143 42 597	1,174 45 119 36 974	21,111 1,080 4,451 2,016 13,564	23,098 1,527 3,234 2,094 16,243	9 1 - 1 7	25 - 15 1 9	15 4 - 4 7	9 2 3 3 1	18 1 9 3 5	18 2 3 2 11	
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	342 5 6 2 70 40 115 41 63	397 4 5 2 74 13 186 37 76	7,124 328 64 206 911 748 3,438 699 730	9,246 309 501 217 2,105 1,345 3,407 483 879	24 1 3 1 6 1 3 8 1	25 2 3 11 7 N	32 8 4 3 10 - 5 1 1	17 - 2 5 1 4 5 -	11 - 2 5 - 3 1 -	18 - 3 3 - 3 5 1	
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	1,453 148 35 1,230 5 35	1,701 88 45 1,541 6 21	23,723 3,400 1,196 17,807 651 669	29,902 3,306 1,611 23,570 553 862	93 N 2 91 -	91 N 7 84 -	56 5 7 41 3	38 5 13 20 -	18 7 8 - 3	38 16 10 12 -	
Guam P.R. 187 V.I. 16 Amer. Samoa C.N.M.I.	13 413 10 -	1 142 - - -	UU	126 - - U U	- U -	- - U U	N 4 U -	N U U U U		U U U	

TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending April 8, 2000, and April 10, 1999 (14th Week)

N: Not notifiable U: Unavailable -: no reported cases C.N.M.I.: Commonwealth of Northern Mariana Islands individual cases may be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS). i Updated monthly from reports to the Division of HIV/AIDS Prevention–Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention, last update March 26, 2000. i Chlamydia refers to genital infections caused by *C. trachomatis*. Totals reported to the Division of STD Prevention, NCHSTP.

	Gonorrhea			atitis IA,NB	Legio	nellosis		rme ease
- Reporting Area	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999
UNITED STATES	70,757	93,601	587	949	172	231	824	1,233
NEW ENGLAND Maine N.H. Vt. Mass. R.I. Conn.	1,606 18 25 14 707 157 685	1,930 15 20 15 770 148 962	19 - 1 18 -	3 - 2 1 -	10 2 - 3 - 3	15 2 3 4 1 3	80 17 23 40	274 1 - 118 8 147
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	4,851 1,462 108 623 2,658	11,326 1,467 4,495 1,979 3,385	13 13 - -	37 19 - 18	29 15 - 14	63 15 8 5 35	584 272 3 309	682 202 18 126 336
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	15,157 3,581 1,449 4,608 4,455 1,064	16,861 4,571 1,849 5,181 4,040 1,220	61 - 5 56 -	516 - 10 140 366	50 24 12 1 8 5	70 19 5 10 22 14	5 5 - - U	48 12 1 2 1 32
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. S. Dak. Nebr. Kans.	2,360 670 199 485 4 63 241 698	4,225 753 257 2,022 21 44 488 640	96 - 87 - 1 8	51 - 44 - 1 6	12 1 3 - 1 - 2	8 - 3 - 1 1 -	30 6 1 5 - - 18	22 7 2 5 1 - 7
S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	19,433 435 1,895 642 2,668 118 4,874 574 3,310 4,917	27,138 467 3,707 1,842 2,565 164 5,036 2,760 4,927 5,670	29 - - 2 7 - 17	65 - - - - - - - - - - - - - - - - - - -	34 2 9 3 N 4 2 2 12	27 2 4 0 N 5 5 5	98 9 70 6 4 4 - 5	140 7 109 1 3 3 15 1 - 1
E.S. CENTRAL Ky. Tenn. Ala. Miss.	8,734 889 2,581 3,450 1,814	10,017 979 2,993 3,183 2,862	114 15 26 3 70	64 5 30 1 28	5 3 1 1	14 7 5 2		17 1 5 6 5
W.S. CENTRAL Ark. La. Okla. Tex.	11,330 541 3,289 896 6,604	13,146 722 2,986 1,101 8,337	133 3 44 - 86	103 4 78 3 18	1 - - 1	1 - 1 -		- - - -
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	2,657 4 18 949 140 1,168 87 287	2,533 8 26 9 588 229 1,280 52 341	72 1 44 10 4 10 - 3	71 4 28 9 10 13 1 2	13 - 1 6 - 2 3 -	15 - - 1 1 1 6 6	1 - - - 1 -	3 - - 1 - 1 - 1 -
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	4,629 615 138 3,714 79 83	6,425 564 239 5,387 106 129	50 5 9 36 -	39 2 4 33 -	18 5 N 13 -	18 4 N 14 -	26 - 1 25 - N	47 - 1 46 - N
Guam P.R. V.I. Amer. Samoa C.N.M.I.	- 71 - -	18 103 U U U	- 1 - -	- U U U		- U U U	N - -	N U U U

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States,	
weeks ending April 8, 2000, and April 10, 1999 (14th Week)	

N: Not notifiable U: Unavailable

- : no reported cases

	weekse	enaing Ap	5/11 0, 200	JU, and Ap) 	99 (14th W Salmon		
	Ma	aria	Rabie	s, Animal	NET			ILIS
Reporting Area	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999
UNITED STATES	205	305	1,142	1,434	5,548	6,566	3,183	5,842
NEW ENGLAND Maine N.H. Vt. Mass. R.I. Conn.	6 1 - 1 2 - 2	5 - - 5 - -	149 38 3 9 48 51	227 39 16 43 48 21 60	387 31 24 31 214 9 78	371 27 14 14 216 18 82	312 12 20 17 187 12 64	394 18 13 16 218 32 97
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	24 11 8 - 5	95 21 41 24 9	231 175 U 34 22	281 181 U 60 40	547 194 191 162	971 188 299 234 250	652 181 217 83 171	695 216 276 197 6
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	23 3 1 10 9	34 4 5 14 8 3	8 2 - 6 -	11 2 - 9 -	798 209 85 253 142 109	1,003 217 54 313 237 182	365 137 46 1 127 54	875 169 67 310 230 99
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. Nebr. Kans.	9 4 - - 1 4	14 2 3 7 - - 2	104 22 17 2 21 18 - 24	195 25 26 6 30 48 1 59	294 42 40 105 4 16 35 52	404 111 47 90 2 13 31 110	276 81 25 91 15 17 22 25	440 157 42 125 16 21 32 47
S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	58 21 22 15 6 1 13	67 - 21 6 12 1 6 - 6 15	498 10 112 123 30 109 34 45 35	498 11 114 112 25 111 43 46 36	1,095 15 162 1 123 27 190 94 175 308	1,190 20 140 24 140 20 243 68 236 299	564 11 111 U 86 19 103 68 166	1,036 27 158 U 129 24 206 76 287 129
E.S. CENTRAL Ky. Tenn. Ala. Miss.	10 2 1 6 1	6 2 2 2	40 9 23 8	68 17 23 28	295 64 67 111 53	355 74 96 107 78	121 23 67 23 8	228 52 93 70 13
W.S. CENTRAL Ark. La. Okla. Tex.	1 - 1 -	11 2 7 1 1	15 - - 15 -	31 - 31	356 59 27 59 211	476 61 75 59 281	364 22 84 35 223	455 49 83 45 278
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	15 1 - 8 - 2 2 2 2	14 2 1 - 4 2 4 1 -	45 10 - 21 - 3 11 - -	40 16 11 1 12 -	519 20 34 7 129 48 167 71 43	521 8 17 6 164 62 150 71 43	307 - 3 97 28 123 56	505 1 25 8 162 60 134 79 36
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	59 3 6 49 - 1	59 3 7 44 5	52 - 42 10 -	83 - 1 78 4 -	1,257 69 61 1,058 17 52	1,275 84 89 1,016 8 78	222 103 77 8 34	1,214 174 128 839 5 68
Guam P.R. V.I. Amer. Samoa C.N.M.I.		- U U U	- 8 - - -	26 U U U	- 7 - -	17 100 U U U		U U U U

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States,
weeks ending April 8, 2000, and April 10, 1999 (14th Week)

N: Not notifiable U: Unavailable -: no reported cases *Individual cases may be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS).

		Shige				ohilis	Tuberculosis			
	NET Cum.	Cum.	Cum.	HLIS Cum.	(Primary & Cum.	Secondary)	Tube Cum.	rculosis Cum.		
Reporting Area	2000	1999	2000	1999	2000	1999	2000	1999 [†]		
UNITED STATES	3,442	3,254	1,353	1,726	1,521	1,789	2,268	3,397		
NEW ENGLAND Maine	72 2	79 1	51	72	24	20	71	95 3		
N.H.	1	5	1	5	-	-	2	-		
Vt. Mass.	1 48	4 50	37	3 47	20	1 11	- 48	50		
R.I. Conn.	7 13	11 8	4 9	8 9	1 3	1 7	7 14	15 27		
MID. ATLANTIC	308	271	233	152	40	81	467	525		
Upstate N.Y. N.Y. City	181 97	57 90	73 105	20 76	2 8	7 30	38 274	55 259		
N.J. Pa.	30	81 43	23 32	56	6 24	20 24	123 32	126 85		
Fa. E.N. CENTRAL	541	43 552	32 181	- 284	365	24	263	288		
Ohio	40 77	171 19	25 9	24 9	20 125	24 77	31 16	68 19		
Ind. III.	180	216	2	189	113	129	172	135		
Mich. Wis.	198 46	71 75	139 6	48 14	88 19	49 9	24 20	49 17		
W.N. CENTRAL	244	198	125	148	19	46	116	120		
Minn. Iowa	47 44	26 2	49 21	29 3	2 8	5 3	42 8	48 6		
Mo. N. Dak.	117 1	126 1	43	100 2	5	32	48	48 1		
S. Dak. Nebr.	1 22	4 13	- 8	25	2	- 3	3 4	3		
Kans.	12	26	4	7	2	3	11	10		
S. ATLANTIC Del.	497 3	538 7	84 2	123 2	481 2	649 1	431	647 5		
Md.	27	31	8	5	91	137	58	58		
D.C. Va.	16	19 19	U 13	U 5	16 36	37 46	2	12 44		
W. Va. N.C.	2 32	3 66	2 11	1 35	1 151	2 142	9 66	11 89		
S.C. Ga.	5 59	31 57	2 25	11 19	11 83	65 118	18 128	85 124		
Fla.	353	305	21	45	90	101	150	219		
E.S. CENTRAL Ky.	167 36	336 34	85 19	189 24	226 22	317 34	142 6	210 30		
Tenn. Ala.	86 9	239 39	63 1	148 16	147 34	154 79	65 71	70 83		
Miss.	36	24	2	1	23	79 50	-	27		
W.S. CENTRAL Ark.	311 58	522 35	287 3	575 21	205 16	254 25	56 37	524 28		
La.	19	43	45	36	59	44	-	U		
Okla. Tex.	8 226	130 314	5 234	33 485	47 83	64 121	19 -	25 471		
MOUNTAIN	252	182	73	112	49	51	104	99		
Mont. Idaho	1 23	3	-	3	-	-	4	-		
Wyo. Colo.	1 33	2 34	1 17	1 26	- 1	-	- 14	Ū		
N. Mex. Ariz.	28 103	24 94	13 32	16 50	6 40	- 50	17 43	14 53		
Utah Nev.	12 51	13 9	10	13 3	- 2	1	7 19	11 21		
PACIFIC	1,050	576	234	71	112	83	618	889		
Wash. Oreg.	187 76	20 16	182 45	37 19	13	11 1	39	45 26		
Calif.	768	524	-	-	97	69	537	763		
Alaska Hawaii	7 12	16	1 6	15	-	1 1	15 27	13 42		
Guam	-	3	U	U	-	-	-	-		
P.R. V.I.	1	20 U	U U	U U	24	59 U	-	41 U		
Amer. Samoa C.N.M.I.		U U	U U	U U	-	U U		U U		
N: Not notifiable		vailabla	1 00 0000	rtad assas						

TABLE II. (Cont'd) Provisional cases of selecte weeks ending April 8, 2000, and A		5,
Shigellosis*	Synphilis	

	H. influ	ienzae,	ŀ	е			Meas	les (Rubec	ola)			
	inva		A		В		Indige		Impo		Tota	
Reporting Area	Cum. 2000 [†]	Cum. 1999	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999	2000	Cum. 2000	2000	Cum. 2000	Cum. 2000	Cum. 1999
UNITED STATES	335	351	3,099	5,001	1,236	1,619	-	4	-	2	6	27
NEW ENGLAND	19	23	78	54	12	47	-	-	-	-	-	2
Maine N.H.	1 6	2 4	4 8	2 6	1 6	- 4	U	-	U	-	-	- 1
Vt.	2	3	3	1	2	1	-	-	-	-	-	-
Mass. R.I.	6	10	33	19 2	3	22 5	-	-	-	-	-	1
Conn.	4	4	30	24	-	15	-	-	-	-	-	-
MID. ATLANTIC Upstate N.Y.	47 22	50 22	127 62	318 69	124 26	238 48	-	-	-	-	-	-
N.Y. City	10	15	65	88	20 98	77	-	-	-	-	-	-
N.J. Pa.	11 4	12 1	-	39 122	-	30 83	-	-	-	-	-	-
E.N. CENTRAL	42	52	404	1,066	131	148	_	3		_	3	
Ohio	17	21	104	231	30	30	-	2	-	-	2	-
Ind. III.	4 18	5 21	15 136	38 197	5 2	8	-	-	-	-	-	-
Mich.	3	5	136	569	93	103	-	1	-	-	1	-
Wis.	-	-	13	31	1	7	-	-	-	-	-	-
W.N. CENTRAL Minn.	14 7	27 11	341 28	252 18	66 4	88 12	-	1	-	-	1	-
lowa Mo.	- 3	4 5	35 188	43 134	14 28	15 41	-	-	-	-	-	-
N. Dak.	1	-	-	-	- 20	- 41	-	-	-	-	-	-
S. Dak. Nebr.	- 1	1 2	- 10	8 23	- 8	- 9	Ū	-	Ū	-	-	-
Kans.	2	4	80	26	12	11	-	1	-	-	1	-
S. ATLANTIC	102	74	377	437	289	254	-	-	-	-	-	-
Del. Md.	24	21	41	1 102	- 35	- 58	-	-	-	-	-	-
D.C. Va.	20	2 9	2 46	16	6 37	6	-	-	-	-	-	-
W. Va.	2	1	46 30	37 5	2	26 5	-	-	-	-	-	-
N.C. S.C.	8 4	12 2	63 11	41 5	81 2	63 31	-	-	-	-	-	-
Ga.	27	19	48	148	45	33	-	-	-	-	-	-
Fla.	17	8	136	82	81	32	-	-	-	-	-	-
E.S. CENTRAL Ky.	18 9	28 5	95 12	126 23	81 18	126 9	-	-	-	-	-	-
Ténn.	6 3	11	21 20	53	28 7	55	-	-	-	-	-	-
Ala. Miss.	-	10 2	20 42	27 23	28	35 27	-	-	-	-	-	-
W.S. CENTRAL	18	26	480	1,120	57	214	-	-	-	-	-	2
Ark. La.	- 3	-7	51 11	12 45	17 18	15 53	-	-	-	-	-	-
Okla.	15	17	102	168	22	40	-	-	-	-	-	-
Tex.	-	2	316	895	-	106	-	-	-	-	-	2
MOUNTAIN Mont.	44	38 1	236 1	459 5	108 3	134 7	-		-	-	-	-
Idaho	2	1	11	16	4	7	.ī	-	.ī	-	-	-
Wyo. Colo.	11	1 2	6 49	2 85	22	2 25	U -	-	U	-	-	-
N. Mex. Ariz.	10 18	10 20	26 113	11 279	32 37	37 30	-	-	-	-	-	-
Utah	3	3	15	18	3	7	-	-	-	-	-	-
Nev.	-	-	15	43	7	19	-	-	-	-	-	-
PACIFIC Wash.	31 2	33	961 50	1,169 76	368 10	370 11	-	-	-	2	2	23 5
Oreg.	9	13	61	75	26	29	U	-	U	-	-	8
Calif. Alaska	9 1	17 2	847 3	1,013 3	324 3	319 7	-	-	-	2	2	10
Hawaii	10	1	-	2	5	4	-	-	-	-	-	-
Guam P.R.	-	- 1	- 19	2 49	- 12	2 56	U	-	U	-	-	-
V.I.	-	U	-	U	-	U	Ū	-	U	-	-	U
Amer. Samoa C.N.M.I.	-	U U	-	U U	-	U U	U U	-	U U	-	-	U U
N. Natastifiable	-			0		0	5		<u> </u>			0

TABLE III. Provisional cases of selected notifiable diseases preventable by vaccination, United States, weeks ending April 8, 2000, and April 10, 1999 (14th Week)

N: Not notifiable U: Unavailable - : no reported cases *For imported measles, cases include only those resulting from importation from other countries. 'Of 74 cases among children aged <5 years, serotype was reported for 31 and of those, 6 were type b.

	Mening Dis	jococcal ease		Mumps	• • •		Pertussis			Rubella	
Reporting Area	Cum. 2000	Cum.	2000	Cum. 2000	Cum. 1999	2000	Cum. 2000	Cum. 1999	2000	Cum.	Cum.
UNITED STATES	700	1999 775	2000 5	<u>1 2000 1</u> 105	113	<u>2000</u> 59	1,013	1,535	2000	2000 12	1999 15
NEW ENGLAND Maine N.H. Vt. Maca	40 3 2	41 3 5 2	U	2 - - -	3 - 1 -	13 U 5	274 9 48 60	141 - 19 9	U -	5 - 1 -	4 - - -
Mass. R.I. Conn.	25 1 6	26 2 3	-	- 1 1	2 - -	6 - 2	139 7 11	106 2 5	-	3 - 1	4 - -
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	62 13 15 16 18	80 20 26 14 20	2 2 - -	7 5 - 2	15 2 3 - 10	17 6 - 11	101 64 - 37	308 258 10 7 33		2 2 - -	1 1 - -
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	114 24 18 30 32 10	123 46 6 42 16 13		11 3 - 3 5 -	16 6 - 4 6 -	4 - 1 2 1 -	149 108 9 13 9 10	154 89 24 16 17			- - - - -
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. Nebr. Kans.	55 3 12 35 1 2 1 1	104 25 18 34 - 5 5 7	- - - - - U	10 - 3 1 - - 4 2	3 - 2 1 - - - -	3 2 1 - - U	37 16 9 4 1 1 2 4	47 9 10 - 2 1 25	- - - - U	2 - - - - - 2	1 - - - 1 -
S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	114 11 19 3 21 6 22 32	106 2 20 1 16 16 16 16 18	1 - - - 1 -	13 - - 2 - 5 -	17 4 1 2 4 2 4 2 4	2	78 1 21 5 - 28 14 9 -	74 - 28 - 7 - 22 6 6 5		3 - - - - 3 -	2 - - - - - - - - - - - - - - - - - - -
E.S. CENTRAL Ky. Tenn. Ala. Miss.	50 11 22 14 3	66 12 22 21 11	- - - -	1 - - 1 -	3 - 1 2	1 - - 1 -	23 13 1 8 1	34 9 17 6 2			- - -
W.S. CENTRAL Ark. La. Okla. Tex.	43 5 13 10 15	61 14 31 13 3	- - -	1 1 - -	15 - 2 1 12	- - -	5 5 - -	39 4 2 3 30	-	-	5 - - 5
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	47 1 6 7 10 7 15 6 2	62 - 8 2 18 7 19 4 4	- - - - - - - - -	7 1 - 1 1 - 2 2	7 - - 2 N - 4 1	13 - U 10 3 - -	223 1 32 118 48 17 4 3	213 1 83 2 49 12 40 24 24 2	- - - - - -		1 - - - - 1 -
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	175 13 19 140 1 2	132 17 29 78 4 4	2 - N 2 -	53 2 N 50 1	34 N 28 1 5	6 3 U 3 -	123 44 18 54 4 3	525 223 8 276 2 16	U		1 - 1 - -
Guam P.R. V.I. Amer. Samoa <u>C.N.M.I.</u>	-	- 7 U U U	U U U U	- - -	1 U U U	U U U U		1 U U U	U U U U		- - U U U

TABLE III. (Cont'd) Provisional cases of selected notifiable diseases preventable by vaccination, United States, weeks ending April 8, 2000, and April 10, 1999 (14th Week)

N: Not notifiable

U: Unavailable

- : no reported cases

		All Cau	ises, By	Age (Ye	-		P&I [†]			All Cau	ises, By	Age (Y	ears)		P&I⁺
Reporting Area	All Ages	≥65	45-64	25-44	1-24	<1	Total	Reporting Area	All Ages	≥65	45-64	25-44	1-24	<1	Total
NEW ENGLAND Boston, Mass. Bridgeport, Conn Cambridge, Mass Fall River, Mass. Hartford, Conn. Lowell, Mass. Lynn, Mass. New Bedford, Ma New Haven, Conn Providence, R.I. Somerville, Mass. Springfield, Mass Waterbury, Conn.	23 19 52 28 12 ss. 20 . 33 . U 4 . 45 22	343 73 29 20 17 37 24 9 15 20 U 34 34 9 20	8 1	26 6 3 1 - 5 1 2 - 3 U - 1 1 2	8 1 - - 2 U - 1	13 8 2 - - - - - - - - - - - - - - - - - -	59 17 3 3 - 7 4 1 1 U 2 5 2 2	S. ATLANTIC Atlanta, Ga. Baltimore, Md. Charlotte, N.C. Jacksonville, Fla. Norfolk, Va. Richmond, Va. Savannah, Ga. St. Petersburg, Fla. Washington, D.C. Wilmington, Del E.S. CENTRAL	124 56 56 1a. 33 185 C. 253	740 U 67 101 81 39 38 40 27 132 134 12 574	227 U 21 16 27 29 7 9 0 2 39 59 8 197	83 U 14 5 9 9 5 3 4 1 10 23 - 67	32 U 5 1 3 5 2 2 1 2 1 10 - 22	50 U 2 4 6 - 3 4 1 3 26 - 15	79 U 10 8 15 10 5 2 5 5 12 7 - 48
Worcester, Mass. MID. ATLANTIC Albany, N.Y. Allentown, Pa. Buffalo, N.Y. Camden, N.J. Elizabeth, N.J. Erie, Pa.§	56 2,173 59 U 71 28 17 49	43 1,543 44 U 51 20 15 37	8 387 9 U 13 6 1 8	3 164 3 U 7 2 - 3	1 36 3 U - -	42 - - - 1 1	13 120 3 U 7 1 2 3	Birmingham, Ala Chattanooga, Te Knoxville, Tenn. Lexington, Ky. Memphis, Tenn. Mobile, Ala. Montgomery, Al Nashville, Tenn.	a. 164 nn. 93 113 51 192 72	107 69 75 37 117 50 29 90	33 16 30 8 47 13 14 36	19 3 7 3 19 5 3 8	341 152 15	2 1 2 4 2 1 3	18 3 5 6 2 7
Jersey City, N.J. New York City, N.J. Paterson, N.J. Philadelphia, Pa. Philadelphia, Pa. Rochester, N.Y. Schenectady, N.Y. Scranton, Pa.§ Syracuse, N.Y. Trenton, N.J. Utica, N.Y. Yonkers, N.Y.	U 15 327 103 31 153	22 749 U 8 215 77 27 114 15 25 81 19 24 U	9 196 U 3 64 13 4 23 7 7 17 6 5 U	10 80 29 6 - 8 1 3 4 4 1 U	20 U 6 1 3 - 3 - U	3 10 1 12 6 - 5 - 2 1 - U	35 U 30 8 2 13 1 3 8 3 1 U	W.S. CENTRAL Austin, Tex. Baton Rouge, La Corpus Christi, 1 Dallas, Tex. El Paso, Tex. Ft. Worth, Tex. Houston, Tex. Little Rock, Ark. New Orleans, La San Antonio, Te Shreveport, La. Tulsa, Okla.	Fex. 56 189 111 125 408 68 . 74	958 61 19 45 118 72 75 227 41 35 138 38 89	348 21 7 8 37 26 33 104 18 10 43 12 29	129 11 2 21 6 7 41 6 9 16 2 6	76 2 - 1 9 6 31 12 6 1 12	34 1 4 1 5 2 8 5 3 1	126 2 2 12 6 10 43 9 3 16 7 10
E.N. CENTRAL Akron, Ohio Canton, Ohio Chicago, III. Cincinnati, Ohio Cleveland, Ohio Columbus, Ohio Dayton, Ohio Detroit, Mich. Evansville, Ind. Fort Wayne, Ind.	2,087 61 35 421 115 111 194 139 173 52 61	1,445 37 29 265 74 68 128 103 103 43 47	424 9 6 102 28 28 41 26 38 8 11	132 4 37 5 9 19 6 24 - 2	28 1 6 2 1 2 3 5 -	56 10 9 6 5 4 1 3 1	173 4 49 11 5 16 5 9 5 4	MOUNTAIN Albuquerque, N Boise, Idaho Colo. Springs, C Denver, Colo. Las Vegas, Nev. Ogden, Utah Phoenix, Ariz. Pueblo, Colo. Salt Lake City, U Tucson, Ariz.	65 olo. 44 126 229 32 183 29	695 63 42 33 77 150 24 116 19 75 96	209 19 11 4 28 56 6 34 6 20 25	97 11 8 5 11 15 1 22 4 12 8	27 1 5 6 1 7 - 2 4	19 2 3 1 5 2 - 4 - 2	82 5 4 16 13 1 7 2 18 16
Gary, Ind. Grand Rapids, Mi Indianapolis, Ind. Lansing, Mich. Milwaukee, Wis. Peoria, III. Rockford, III. South Bend, Ind. Toledo, Ohio Youngstown, Ohi	11 2011 2012 2013 2013 2013 2013 2013 20	8 34 120 33 102 45 44 38 76 48		1 5 1 4 1 2 8 2	1 2 1 2 1 - 1 -	- 4 - 3 2 1	4 22 4 15 4 3 1 6 2	PACIFIC Berkeley, Calif. Fresno, Calif. Glendale, Calif. Honolulu, Hawa Long Beach, Cal Los Angeles, Cal Pasadena, Calif. Portland, Oreg. Sacramento, Cal	if. 97 lif. 702 17 152 lif. 177	1,480 20 35 32 61 77 529 14 114 130	323 4 10 3 13 15 110 3 22 30	108 1 3 2 39 - 8 12	31 - - 2 - 14 - 4 2	36 3 1 - 3 10 - 4 3	169 4 6 2 13 56 4 9 18
W.N. CENTRAL Des Moines, Iowa Duluth, Minn. Kansas City, Kans Kansas City, Mo. Lincoln, Nebr. Minneapolis, Min Omaha, Nebr. St. Paul, Minn. Wichita, Kans.	29 . 41 90 41	452 U 20 27 57 31 97 65 56 61 38	112 9 10 14 7 13 7 18 14 20	27 U 2 6 3 6 2 5 2 1	20 U 2 6 2 2 3 4 1	15 U 7 2 4 2	45 U 1 3 4 2 8 6 <u>1</u> 3 4 3 4 3 4 3 4 3 4 5 4 5 4 5 4 5 4 5 4	San Diego, Čalif San Francisco, C San Jose, Calif. Santa Cruz, Calif Seattle, Wash. Spokane, Wash. Tacoma, Wash. TOTAL	alif. U 175 f. 27 112	131 U 132 22 82 34 67 8,230	40 U 26 4 15 9 19 2,308	9 U 10 - 10 2 5 833	3 U 2 1 3 - 280	4 U 2 1 - 280	22 U 18 1 6 5 901

TABLE IV. Deaths in 122 U.S. cities,* week ending April 8, 2000 (14th Week)

U: Unavailable -:no reported cases *Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of 100,000 or more. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included. *Pneumonia and influenza. *Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks. *Total includes unknown ages.

Contributors to the Production of the MMWR (Weekly)

Weekly Notifiable Disease Morbidity Data and 122 Cities Mortality Data

Samuel L. Groseclose, D.V.M., M.P.H.

State Support Team Robert Fagan Jose Aponte Paul Gangarosa, M.P.H. Gerald Jones David Nitschke Carol A. Worsham **CDC Operations Team** Carol M. Knowles Deborah A. Adams Willie J. Anderson Patsy A. Hall Pearl Sharp Kathryn Snavely

The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis for paper copy. To receive an electronic copy on Friday of each week, send an e-mail message to *listserv@listserv.cdc.gov*. The body content should read SUBscribe mmwr-toc. Electronic copy also is available from CDC's World-Wide Web server at http://www.cdc.gov/or from CDC's file transfer protocol server at ftp.cdc.gov. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone (202) 512-1800.

(202) 512-1800. Data in the weekly MMWR are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Address inquiries about the MMWR Series, including material to be considered for publication, to: Editor, MMWR Series, Mailstop C-08, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333; telephone (888) 232-3228. All material in the MMWR Series is in the public domain and may be used and reprinted without permission; elisted as the public domain and may be used and reprinted without permission;

citation as to source, however, is appreciated.

Director, Centers for Disease Control and Prevention Jeffrey P. Koplan, M.D., M.P.H. Acting Deputy Director for Science and Public Health, Centers for Disease Control and Prevention Lynne S. Wilcox, M.D., M.P.H.	Acting Director, Epidemiology Program Office Barbara R. Holloway, M.P.H. Editor, <i>MMWR</i> Series John W. Ward, M.D. Acting Managing Editor, <i>MMWR</i> (weekly)	Writers-Editors, MMWR (weekly) Jiil Crane David C. Johnson Teresa F. Rutledge Desktop Publishing Morie M. Higgins Cheryle R. Reynolds	
ALLS Covernment	Caran R. Wilbanks		
×0.3. doveniment	<u>Printing Office: 2000-533-206/2</u>	Official Business Penalty for Private Use \$300 Return Service Requested	DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention (CDC) Atlanta, Georgia 30333

POSTAGE & FEES PAID PHS/CDC Permit No. G-284 FIRST-CLASS MAIL

The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis for paper copy. To receive an electronic copy on Friday of each week, send an e-mail message to listserv@listserv.cdc.gov. The body content should read SUBscribe mmwr-toc. Electronic copy also is available from CDC's World-Wide Web server at http://www.cdc.gov/or from CDC's file transfer protocol server at ftp.cdc.gov. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone (202) 512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Address inquiries about the *MMWR* Series, including material to be considered for publication, to: Editor, *MMWR* Series, Mailstop C-08, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333; telephone (888) 232-3228. All material in the *MMWR* Series is in the public domain and may be used and reprinted without permission;

citation as to source, however, is appreciated.

	Director, Centers for Disease Control and Prevention Jeffrey P. Koplan, M.D., M.P.H.	Acting Director, Epidemiology Program Office Barbara R. Holloway, M.P.H.	MMWR (weekl Jill Crane		
Acting Deputy Director for Science and Public Health, Centers for Disease Control and Prevention Lynne S. Wilcox, M.D., M.P.H.	Editor, <i>MMWR</i> Series John W. Ward, M.D.	David C. Joł Teresa F. Ru	utledge		
	Acting Managing Editor, MMWR (weekly) Caran R. Wilbanks	Desktop Publishing Morie M. Higgins Cheryle R. Reynolds			
	☆U.S. Government Printing Office: 2000-533-206/28004 Region IV				
			Official Business Penalty for Private Use \$300 Return Service Requested	UNITED STATES GOVERNMENT PRINTING OFFICE SUPERINTENDENT OF DOCUMENTS Washington, D.C. 20402	

BULK RATE Postage & Fees Paid Permit No. G-26 GPO